Zacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 Million

Equities research analysts predict that Kamada Ltd. (NASDAQ:KMDA) will report sales of $24.84 million for the current quarter, according to Zacks. Two analysts have made estimates for Kamada’s earnings, with the highest sales estimate coming in at $25.18 million and the lowest estimate coming in at $24.50 million. Kamada reported sales of $19.37 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 28.2%. The firm is expected to announce its next earnings report on Thursday, November 9th.

On average, analysts expect that Kamada will report full year sales of $24.84 million for the current year. For the next financial year, analysts expect that the business will post sales of $126.66 million per share, with estimates ranging from $120.80 million to $132.51 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Kamada.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The company had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. Kamada’s revenue was up 70.7% compared to the same quarter last year.

A number of brokerages have issued reports on KMDA. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. ValuEngine lowered Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Finally, TheStreet lowered Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Kamada has a consensus rating of “Hold” and a consensus target price of $8.50.

COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Kamada Ltd. (KMDA) Will Announce Quarterly Sales of $24.84 Million” was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/10/31/zacks-brokerages-expect-kamada-ltd-kmda-will-announce-quarterly-sales-of-24-84-million.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. raised its position in Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 4,000 shares during the period. Vanguard Group Inc. raised its position in Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after purchasing an additional 28,382 shares during the period. Renaissance Technologies LLC raised its position in Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after purchasing an additional 37,800 shares during the period. Navellier & Associates Inc purchased a new stake in Kamada in the second quarter valued at approximately $303,000. Finally, Paulson & CO. Inc. raised its position in Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the period. 7.25% of the stock is currently owned by institutional investors.

Kamada (KMDA) opened at 5.05 on Tuesday. The company’s market cap is $188.87 million. The company has a 50-day moving average price of $4.81 and a 200 day moving average price of $5.76. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61.

Kamada Company Profile

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Kamada Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kamada Ltd. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit